Keyword: Insys Therapeutics
Another Insys exec faces prison time for an elaborate scheme to pay doctors in return for stepped-up prescriptions for fentanyl spray Subsys.
A federal judge said prosecutors failed to present enough evidence to charge Insys founder John Kapoor on conspiracy in the drugmaker's Subsys sales.
As Insys reaches the last days of its bankruptcy liquidation, it's offering to settle its opioid overhang at pennies on the dollar for plaintiffs.
Insys is in fire sale mode as part of its bankruptcy plan, and now it’s been given the go-ahead to sell the opioid that helped get it there.
Hikma says it has picked up some pipeline products and nasal and sublingual spray equipment from Insys Therapeutics' bankruptcy.
When Insys settled with the feds for $225 million, the drugmaker hoped it had put its troubled past behind it. Now they’re filing for bankruptcy.
After federal prosecutors bagged multiple former execs, Insys had to know its day of reckoning was near. Now it's here—and it'll cost $225 million.
Purdue took a big hit when it settled with Oklahoma over claims it misleadingly advertised its powerful opioid, OxyContin. Now more states want in.
Insys founder John Kapoor was found guilty on federal racketeering charges in a landmark case nailing C-level executives in the U.S. opioid epidemic.